We invite you to participate in a short, focused survey designed to understand clinical preferences, therapeutic choices, and real-world challenges faced by oncologists in managing metastatic non-small cell lung cancer (NSCLC) — including ALK-positive subtypes. Take a moment to share your clinical perspective and make a difference in future care standards.